Login to Your Account



Merck wins FDA approval for C. diff-targeting monoclonal antibody Zinplava

By Michael Fitzhugh
Staff Writer

Monday, October 24, 2016

Merck & Co. Inc. succeeded in overcoming regulatory friction to win FDA approval for Zinplava, a monoclonal antitoxin antibody targeting CDI in adults at high risk for recurrence of the infection.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription